Trends in Parasitology
LettersArtemisinin resistance: how can we find it?
References (11)
Averting a malaria disaster
Lancet
(1999)Two patients with falciparum malaria and poor in vivo responses to artesunate
Trans. R. Soc. Trop. Med. Hyg.
(1998)Artemisinin: mechanisms of action, resistance and toxicity
Int. J. Parasitol.
(2002)- et al.
Qinghaosu
Lancet
(1993) Fake artesunate in southeast Asia
Lancet
(2001)
Cited by (38)
Recent advances in the synthesis and antimalarial activity of 1,2,4-trioxanes
2024, Bioorganic ChemistryGlobal distribution of polymorphisms associated with delayed Plasmodium falciparum parasite clearance following artemisinin treatment: Genotyping of archive blood samples
2015, Parasitology InternationalCitation Excerpt :In both countries, ACT was already implemented when our sampling was carried out. This may be due to the fact that there were no clear criteria for assessing ACT ‘resistance’ until the mid-2000s [32], and thus, the potential emergence of ACT-resistant parasites might have been missed at the time our sampling was carried out. Additionally/alternatively, delayed-clearance associated SNPs at MAL10-688956 and MAL13-1718319 alone may not be sufficient for the acquirement of the ‘resistance’ phenotype; rather, these polymorphisms might be necessary prior to the attainment of ‘resistance’ through mutation elsewhere in the genome.
Artemisinin resistance in Plasmodium falciparum: What is it really?
2013, Trends in ParasitologyCitation Excerpt :The causes for delayed parasite clearance times are likely to be multifactorial, and parasite densities at time of treatment initiation appear to be associated with this phenotype. Nevertheless, given the likelihood that true artemisinin resistance will develop [24], the process by which this may occur needs to be carefully considered. Understanding how resistance to ACTs may evolve and spread will aid efforts to increase the useful lifespan of this important antimalarial therapy.
Ahead of the curve: Next generation estimators of drug resistance in malaria infections
2013, Trends in ParasitologyCitation Excerpt :Malaria parasites are a prime example of this: resistance has evolved to nearly every antimalarial drug in use [1] and appears to be emerging against the current front-line artemisinin derivatives [2–7]. Ensuring the continued efficacy of these important drugs requires good surveillance, early and rapid detection of resistance, and containment of its spread [3,8–13]. Ideally, resistance would be detected when it is at a low level (drug ‘tolerance’) and low frequency in a patient, well before it has become a clinical problem.
Malaria in the Greater Mekong Subregion: Heterogeneity and complexity
2012, Acta TropicaABC - antibiotics-based combinations for the treatment of severe malaria?
2009, Trends in ParasitologyCitation Excerpt :Between 2005 and 2006, the number of doses of ACTs increased from six million to 49 million, of which 45 million were for African countries [1,5]. Although the first cases of genuine artemisinin resistance have recently emerged in a relatively small region along the Cambodia–Thailand border [6–8], in most parts of the world ACTs remain the most potent and fast-acting therapy for the treatment of uncomplicated falciparum malaria [9]. In spite of rising numbers of failures in some regions, the importance of ACTs today is only comparable to that of chloroquine in the mid 20th century [10–12].